Plasma cell leukemia: from biology to treatment

Plasma cell leukemia (PCL) is a very aggressive and rare form of malignant monoclonal gammopathy characterized by the presence of plasmocytes in peripheral blood. It is classified as primary PCL occuring ‘de novo’, or as secondary PCL in patients with relapsed/refractory multiple myeloma. Primary PCL is a distinct clinicopathological entity from myeloma with different cytogenetic abnormalities and molecular findings, which are usually found only in advanced multiple myeloma. The clinical course is aggressive with short remissions and reduced overall survival. The diagnostic criteria are based on the percentage (>20%) and absolute number (2 × 109/L) of plasma cells in peripheral blood. After establishing diagnosis, induction therapy should begin promptly which is aimed to rapid disease control and to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib‐based regimens, followed by high‐dose therapy with autologous stem cell transplantation, are recommended. Allogeneic transplantation can be considered in younger patients. This article reviews recent knowledge of this hematological malignancy that is associated with a very poor prognosis.

[1]  S. Trudel,et al.  Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia , 2015, Leukemia & lymphoma.

[2]  M. Clynes,et al.  Bone Disease in Multiple Myeloma: Pathophysiology and Management , 2014, Cancer growth and metastasis.

[3]  S. Trudel,et al.  Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia , 2013 .

[4]  K. Anderson,et al.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group , 2013, Leukemia.

[5]  G. Jansen,et al.  Proteasome inhibitors in acute leukemia , 2013, Expert review of anticancer therapy.

[6]  P. Richardson,et al.  How I treat plasma cell leukemia. , 2012, Blood.

[7]  A. Palumbo,et al.  Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Ling Zhang,et al.  Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. , 2011, Clinical lymphoma, myeloma & leukemia.

[9]  M. Kersten,et al.  Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT , 2011 .

[10]  S. Lonial,et al.  Hematopoietic Cell Transplantation for Primary Plasma Cell Leukemia: Results from the Center for International Blood and Marrow Transplant Research , 2011, Leukemia.

[11]  P. Galieni,et al.  Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Barbara Kruk,et al.  Flow cytometric immunophenotypic characteristics of plasma cell leukemia. , 2011, Folia histochemica et cytobiologica.

[13]  S. Gujral,et al.  Immunophenotypic profile of plasma cell leukemia: a retrospective study in a reference cancer center in India and review of literature. , 2011, Indian journal of pathology & microbiology.

[14]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[15]  I. Rabinowitz,et al.  Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen , 2010, American journal of hematology.

[16]  S. Iacobelli,et al.  Primary plasma cell leukemia and autologous stem cell transplantation , 2010, Haematologica.

[17]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[18]  Jingqin Luo,et al.  Primary plasma cell leukemia , 2009, Cancer.

[19]  N. Cross,et al.  Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context , 2009, Haematologica.

[20]  I. Attolico,et al.  Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report. , 2009, Leukemia research.

[21]  J. Pretz,et al.  Thalidomide‐induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy , 2009, American journal of hematology.

[22]  Wang Yafei,et al.  A Retrospective Analysis of Thirty-One Cases of Plasma Cell Leukemia from a Single Center in China , 2009, Acta Haematologica.

[23]  P. Musto,et al.  Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. , 2008, Leukemia research.

[24]  M. Goodman,et al.  Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002 , 2008, Cancer Causes & Control.

[25]  Marina Ruggeri,et al.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008, Haematologica.

[26]  P. L. Bergsagel,et al.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. , 2008, Cancer cell.

[27]  P. L. Bergsagel,et al.  Genetic aberrations and survival in plasma cell leukemia , 2008, Leukemia.

[28]  J. Tamburini,et al.  Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy , 2008, Leukemia & lymphoma.

[29]  N. Bolli,et al.  Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia , 2007, Nature Clinical Practice Oncology.

[30]  Y. Ning,et al.  Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma , 2007, British journal of haematology.

[31]  F. Ferrara,et al.  Efficacy and safety of bortezomib in patients with plasma cell leukemia , 2007, Cancer.

[32]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[33]  R. Fonseca,et al.  Clinical significance of TP53 mutation in myeloma , 2007, Leukemia.

[34]  R. Foà,et al.  Thalidomide does not modify the prognosis of plasma cell leukemia patients: Experience of a single center , 2007, Leukemia & lymphoma.

[35]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[36]  Y. Ning,et al.  Multiple myeloma patients with CKS1B gene amplification have a shorter progression‐free survival post‐autologous stem cell transplantation , 2006, British journal of haematology.

[37]  G. Ahmann,et al.  Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma , 2006, Leukemia.

[38]  Y. Natkunam,et al.  Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis. , 2006, American journal of clinical pathology.

[39]  Yongsheng Huang,et al.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.

[40]  S. Trudel,et al.  Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation , 2005, Bone Marrow Transplantation.

[41]  Robert A Kyle,et al.  Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. , 2005, Blood.

[42]  R. Fonseca,et al.  Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Esparís-Ogando,et al.  Bortezomib is an efficient agent in plasma cell leukemias , 2005, International journal of cancer.

[44]  R. Fonseca,et al.  Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem‐cell transplantation and review of the literature , 2005, American journal of hematology.

[45]  P. Mehta,et al.  Primary plasma cell leukaemia. , 2004, The Journal of the Association of Physicians of India.

[46]  Bart Barlogie,et al.  Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.

[47]  E. Vellenga,et al.  CD27‐triggering on primary plasma cell leukaemia cells has anti‐apoptotic effects involving mitogen activated protein kinases , 2004, British journal of haematology.

[48]  H. Goldschmidt,et al.  Dissociation of putative graft‐versus‐haematopoiesis and graft‐versus‐myeloma effects in patients with rapidly progressive multiple myeloma * , 2003, British journal of haematology.

[49]  F. Zhan,et al.  CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high‐risk disease , 2003, British journal of haematology.

[50]  L. Shvidel,et al.  Polyclonal Reactive Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia in a Patient with Staphylococcal Sepsis , 2003, Leukemia & lymphoma.

[51]  J. Vela-Ojeda,et al.  Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia , 2002, Annals of Hematology.

[52]  E. Brambilla,et al.  Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors , 2002, Oncogene.

[53]  R. Bataille,et al.  Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique. , 2001, Blood.

[54]  R. Kyle,et al.  Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. , 1999, Hematology/oncology clinics of North America.

[55]  A. Órfão,et al.  Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. , 1999, Blood.

[56]  R. Bataille,et al.  The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma , 1998, Leukemia.

[57]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[58]  B. Barlogie,et al.  Graft-versus-myeloma effect: proof of principle. , 1996, Blood.

[59]  Terry L. Smith,et al.  High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. , 1991, Annals of internal medicine.

[60]  R. Kyle,et al.  Plasma cell leukemia: an evaluation of response to therapy. , 1987, The American journal of medicine.

[61]  R. Kyle,et al.  Plasma cell leukemia. Report on 17 cases. , 1974, Archives of internal medicine.

[62]  A. Palumbo,et al.  Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia , 2014, Leukemia.

[63]  J. Shah,et al.  New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) , 2014, Leukemia.

[64]  Khanum Memorial,et al.  Bone Disease in Multiple Myeloma: Pathophysiology and Management , 2014 .

[65]  S. Ševčíková,et al.  Prognostic significance of morphological assessment of plasma cells in multiple myeloma. , 2011, Neoplasma.

[66]  S. Janković,et al.  Thirty patients with primary plasma cell leukemia: a single center experience , 2008, Medical oncology.

[67]  F. Leibetseder,et al.  [Plasma cell leukemia]. , 1973, Blut.